TITLE

PPARγ AS A NEW THERAPEUTIC TARGET IN INFLAMMATORY BOWEL DISEASES

AUTHOR(S)
Dubuquoy, L.; Rousseaux, C.; Thuru, X.; Peyrin-Biroulet, L.; Romano, O.; Chavatte, P.; Chamaillard, M.; Desreumaux, P.
PUB. DATE
September 2006
SOURCE
Gut;Sep2006, Vol. 55 Issue 9, p1341
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The peroxisome proliferator activated receptor γ (PPAR-γ) is a nuclear receptor highly expressed in the colon and playing a key role in bacterial induced inflammation. Regulation of colon inflammation by this receptor has been well demonstrated in many experimental models of colitis but also in patients with ulcerative colitis, characterised by impaired expression of PPARγ confined to their colon epithelial cells. Recent data showing that PPARγ was the major functional receptor mediating the common aminosalicylate activities in inflammatory bowel diseases (IBD) have also reinforced the roles of this receptor in the control of intestinal inflammation. The aims of this review are to discuss the potential roles of PPARγ in the physiopathology of IBD, as well as the emerging therapeutic strategies targeting this receptor.
ACCESSION #
22184124

 

Related Articles

  • Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations. Maul, Jochen; Zeitz, Martin // Langenbeck's Archives of Surgery;Jan2012, Vol. 397 Issue 1, p1 

    Background: Ulcerative colitis (UC) is a complex disease in which the interaction of genetic, environmental and microbial factors drives chronic intestinal inflammation that finally leads to extensive tissue fibrosis. Discussion: The present review discusses the current knowledge on genetic...

  • PPARγ in Inflammatory Bowel Disease. Annese, Vito; Rogai, Francesca; Settesoldi, Alessia; Bagnoli, Siro // PPAR Research;2012, Special section p1 

    Peroxisome proliferator-activated receptor gamma (PPARγ) is member of a family of nuclear receptors that interacts with nuclear proteins acting as coactivators and corepressors. The colon is a major tissue which expresses PPARγ in epithelial cells and, to a lesser degree, in macrophages...

  • Dramatic And Long Lasting Efficiency (13 Years) Of Oral 5 Aspirin. Maroy, Bernard // Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p12 

    Introduction: Could 5 ASA be an option in case of cortico-resistant and/or intolerant ulcerative colitis? Case report: A 55-year-old woman was referred for a recent, moderately severe, left-sided ulcerative colitis. The response to corticotherapy was initially fair, then mediocre, complicated by...

  • The Microvacular Thrombi of Colonic Tissue in Ulcerative Colitis. Guobin He; Qin Ouyang; Daiyun Chen; Fengyuan Li; Jingguo Zhou // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2236 

    Abstract  Mucosal microvacular thrombi in rectal biopsies were observed in some ulcerative colitis (UC). Heparin may be effective in steroid resistant UC in some studies, however, the new results of meta-analysis demonstrated a non-significant effect of heparin in controlled...

  • The Role of Zinc and Metallothionein in the Dextran Sulfate Sodium-Induced Colitis Mouse Model. C. Tran; S. Sundar; P. Coyle // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2113 

    Abstract  Zinc (Zn) and its binding protein metallothionien (MT) have been proposed to suppress the disease activity in ulcerative colitis. To determine the role of Zn and MT in the dextran sulfate sodium (DSS)-induced model of colitis in mice, a DSS dose-response study was...

  • Leukocytapheresis (LCAP) in the Management of Chronic Active Ulcerative Colitis—Results of a Randomized Pilot Trial. Jörg Emmrich; Sebastian Petermann; Dietrich Nowak; Ingolf Beutner; Peter Brock; Patrick Mausfeld-Lafdhiya; Stefan Liebe; Wolfgang Ramlow // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2044 

    Abstract  Recent studies suggest that leukocytapheresis with Cellsorba is a valuable therapy for ulcerative colitis after failure of conventional treatment. In this study the potential of leukocytapheresis to induce remission in refractory chronic colitis under the conditions of...

  • Meta-Analysis of the Placebo Response in Ulcerative Colitis. Sagar Garud; Alphonso Brown; Adam Cheifetz; Emily Levitan; Ciaran Kelly // Digestive Diseases & Sciences;Apr2008, Vol. 53 Issue 4, p875 

    Abstract   Purpose The placebo response rate in randomized controlled trials (RCTs) in ulcerative colitis (UC) varies from 0 to 76%. The aims of this study were to quantify the pooled placebo response rate and identify the factors affecting it. Methods We performed a...

  • Abnormalities in colonic mucin may contribute to the persistence of colonic mucosal inflammation.  // Journal of Gastroenterology;2000, Vol. 35 Issue 1, p71 

    Editorial. Deals with the possible contribution of the abnormalities in colonic mucin to the persistence of colonic mucosal inflammation. Percentage of ulcerative colitis patients with circulating antibodies to colonocytes; Number of reported mucin genes; Description of MUC2 mucin; Candidate...

  • A Population-based Ecologic Study of Inflammatory Bowel Disease: Searching for Etiologic Clues. Chris Green; Lawrence Elliott; Carole Beaudoin; Charles N. Bernstein // American Journal of Epidemiology;Oct2006, Vol. 164 Issue 7, p615 

    The authors' objective in this study was to determine geographic variations in the incidence of inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis, in the Canadian province of Manitoba and its association with the sociodemographic, geographic, and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics